Third Contract Secured This Year
Expanding Strategic Partnerships in the U.S. Biomanufacturing Market
Strengthening Global Presence Through Dual-Site Operations in Syracuse and Songdo
Lotte Biologics announced on September 2 that it has signed a contract for contract manufacturing organization (CMO) services with a global biopharmaceutical company headquartered in the United States.
This contract involves securing a project for Phase 3 clinical trials and commercialization of an innovative immunotherapy drug candidate, which is being expanded to multiple indications. Lotte Biologics aims to contribute to the partner company's clinical pipeline expansion and new drug development, while also playing a key role in improving patient access to innovative medicines. The company also plans to explore additional collaboration opportunities upon product approval in the future. The client company has not been disclosed due to a confidentiality agreement, and the contract period runs until 2030.
A representative from Lotte Biologics stated, "Through this partnership, we have once again demonstrated our commercial manufacturing capabilities and quality competitiveness in the global market, while showcasing the geographic advantages of our U.S. production base. By operating the Syracuse Bio Campus in the United States and the Songdo Bio Campus in Korea, which is scheduled to begin operations in 2027, under a unified quality system, we are expanding collaboration with U.S. pharmaceutical and biotech companies, ensuring stable supply, and enhancing our ability to respond quickly and flexibly to demand."
Recently, Lotte Biologics has achieved visible results amid the reshoring trend and supply chain restructuring in the U.S. biomanufacturing sector, leveraging ongoing customer engagement and differentiated capabilities. This year, the company has secured three contracts based on its U.S. production base, further strengthening its strategic partnerships.
The company’s strategy is to further expand cooperation with local U.S. companies and broaden its global customer base. By maximizing the proven quality competitiveness of the Syracuse Bio Campus and the dual-site operation advantages of Syracuse and Songdo, Lotte Biologics plans to offer its own differentiated CDMO (Contract Development and Manufacturing Organization) solutions.
A Lotte Biologics official commented, "This contract was achieved based on firm trust in our global network and technological competitiveness. We will continue to solidify our position as a leading global biomanufacturing hub and work closely with our partners to ensure that innovative therapies are delivered to patients worldwide."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
